Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma has raised approximately SEK 51.9 million through a directed share issue of 2,883,725 new shares, priced at SEK 18.00 each and placed with Swedish and international qualified investors as well as select existing shareholders. Together with an existing cash position of SEK 53.4 million and an increased SEK 40 million credit facility, the move significantly reinforces the company’s balance sheet.
The company expects the new funds to extend its cash runway into the third quarter of 2027, securing uninterrupted progress of its Phase 2b ADVANCE trial in rheumatoid arthritis and Phase 2 programs in virus-induced hyperinflammation. Management says the stronger financial position is intended to reduce near-term financing risk, improve SynAct’s leverage in post-data partnering talks, and enhance its strategic flexibility ahead of multiple clinical readouts projected for 2026, with the goal of maximizing long-term shareholder value.
The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company developing resomelagon (AP1189), an oral resolution therapy that promotes the body’s natural ability to resolve inflammation rather than suppress immunity. Its lead programs target newly diagnosed rheumatoid arthritis as a pre-biologic therapy and severe virus-induced hyperinflammation, including respiratory disease and dengue, aiming at high-impact inflammatory markets.
YTD Price Performance: -12.83%
Average Trading Volume: 137,443
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.05B
See more insights into SYNACT stock on TipRanks’ Stock Analysis page.